Cetuximab or bevacizumab with combi chemo equivalent in KRAS wild-type MCRC

For patients with KRAS wild-type untreated colorectal cancer, adding cetuximab or bevacizumab to combination chemotherapy offers equivalent survival, researchers said.

Source: ScienceDaily Headlines - June 29, 2014 Category: Science Source Type: news